Publication | Open Access
Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture
13
Citations
41
References
2021
Year
Recent clinical experience has demonstrated that adoptive regulatory T (Treg) cell therapy is a safe and feasible strategy to suppress immunopathology <i>via</i> induction of host tolerance to allo- and autoantigens. However, clinical trials continue to be compromised due to an inability to manufacture a sufficient Treg cell dose. Multipotent adult progenitor cells (MAPC<sup>Ⓡ</sup>) promote Treg cell differentiation <i>in vitro</i>, suggesting they may be repurposed to enhance <i>ex vivo</i> expansion of Tregs for adoptive cellular therapy. Here, we use a Good Manufacturing Practice (GMP) compatible Treg expansion platform to demonstrate that MAPC cell-co-cultured Tregs (MulTreg) exhibit a log-fold increase in yield across two independent cohorts, reducing time to target dose by an average of 30%. Enhanced expansion is coupled to a distinct Treg cell-intrinsic transcriptional program characterized by elevated expression of replication-related genes (<i>CDK1, PLK1, CDC20</i>), downregulation of progenitor and lymph node-homing molecules (<i>LEF1 CCR7, SELL</i>) and induction of intestinal and inflammatory tissue migratory markers (<i>ITGA4, CXCR1</i>) consistent with expression of a gut homing (CCR7lo β<sub>7</sub>hi) phenotype. Importantly, we find that MulTreg are more readily expanded from patients with autoimmune disease compared to matched Treg lines, suggesting clinical utility in gut and/or T helper type1 (Th1)-driven pathology associated with autoimmunity or transplantation. Relative to expanded Tregs, MulTreg retain equivalent and robust purity, FoxP3 Treg-Specific Demethylated Region (TSDR) demethylation, nominal effector cytokine production and potent suppression of Th1-driven antigen specific and polyclonal responses <i>in vitro</i> and xeno Graft vs Host Disease (xGvHD) <i>in vivo</i>. These data support the use of MAPC cell co-culture in adoptive Treg therapy platforms as a means to rescue expansion failure and reduce the time required to manufacture a stable, potently suppressive product.
| Year | Citations | |
|---|---|---|
Page 1
Page 1